WO2003007960A1 - Method for protecting human skin against infections and a dermatic for carrying out said method - Google Patents

Method for protecting human skin against infections and a dermatic for carrying out said method Download PDF

Info

Publication number
WO2003007960A1
WO2003007960A1 PCT/RU2002/000116 RU0200116W WO03007960A1 WO 2003007960 A1 WO2003007960 A1 WO 2003007960A1 RU 0200116 W RU0200116 W RU 0200116W WO 03007960 A1 WO03007960 A1 WO 03007960A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
dermatic
protecting
dioxidine
microflora
Prior art date
Application number
PCT/RU2002/000116
Other languages
French (fr)
Russian (ru)
Inventor
Vyacheslav Vitalievich Barbinov
Roman Arikovich Grashin
Aleksey Viktorovich Samtsov
Vladimir Nikolaevich Atamanchuk
Vyacheslav Anatolievich Jurieshev
Sergey Dmitrievich Tsiembalov
Sergey Ivanovich Petrov
Andrey Valerievich Babkin
Original Assignee
Muratov, Igor Aleksandrovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2001119668/14A external-priority patent/RU2001119668A/en
Application filed by Muratov, Igor Aleksandrovich filed Critical Muratov, Igor Aleksandrovich
Publication of WO2003007960A1 publication Critical patent/WO2003007960A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Definitions

  • the invention is available in the field of medicine and may be used.
  • the left hand side of the distributor is ethanol ( ⁇ , 2014085).
  • antibacterial device as a rule, it is used 1 -
  • SIGNIFICANT FOX (DR. 26) In general, a single, simultaneous application of the drug is available at the place
  • the method of protecting the human being from infection is known, including
  • the objective of the invention is to increase the efficiency
  • SIGNIFICANT FOX (DR. 26) The task posed is solved due to the fact that there is a way to protect the human being from infection, which is concluded in the use of
  • an antimicrobial preparation is used from the chynoxaline group.
  • the consumer is using the required volume of waste.
  • dioxidine may be used
  • chinoksidin may be used as a part of an antimicrobial preparation.
  • - antimicrobial can be introduced in quantities of 0.01 - 10.0 wt.%.
  • liposomal form and in the substitute, ⁇ . e. less than for
  • drugs for example, dioxidine
  • the main external device is short-lived and does not accelerate the external
  • the property declared is also that the antimicrobial is used in small substrates, which are mini
  • the invention may be practiced using

Abstract

The invention relates to medicine and can be used for protecting a human being against bacteria or viral infections. The inventive dermatic is embodied in the form of a soap, shampooing, gel or a cream. Anti-infective preparations for example dioxidine in a liposomal form and in a subtherapeutical dosage, for example ranging from 0.01 to 10.0 mass %, are introduced into said dermatic. For a short while, said dermatic is present on the surface of the horny layer of the skin in an aerobic condition thereof without having any time to harmfully affect the microflora thereof, the remainder of the dermatic being easily washed out of the skin surface. The main mass of the dermatic being embodied in the liposomal form penetrates the epidermis of the skin, whereby the bactericide effect of dioxidine is increased by 10-30 times in an aerobic condition and produces a prolonged and maximal action on the microflora within the thickness of the skin and branches thereof, protecting them against a pyoinflammatory process occurring from the inside. Said invention increases the efficiency of antibacterial agents and reduces the harmful action thereof on the useful resident microflora of the skin.

Description

Сποсοб ззщиτы κοжи челοвеκа οτ инφеκций и The method of protection of the skin of the person from infections and
наρужнοе сρедсτвο для егο ρеализацииexternal equipment for its implementation
5 Οбласτь τеχниκи5 Area of technology
Изοбρеτение οτнοсиτся κ οбласτи медицины и мοжеτ быτь ис-The invention is available in the field of medicine and may be used.
ποльзοванο в для защиτы челοвеκа οτ баκτеρиальныχ или виρусныχUsed to protect human beings from bacterial or viral
инφеκций.infections.
Пρедшесτвующий уροвень τеχниκиPREVIOUS LEVEL OF TECHNOLOGY
ю Извесτен сποсοб бορьбы с инφеκциями с исποльзοванием ан-You are aware of a method of dealing with infections using an
τимиκροбнοгο сοсτава, сοдеρжащегο аκτивнο дейсτвующее вещесτвο,Such a consignment containing an active active substance,
связующее, ρасτвορиτель и вοду, в κοτοροм в κачесτве аκτивнο дейсτ-a binder, a distributor and water, as a rule, in the form of an active
вующегο вещесτва исποльзοван сангвиρиτρин, связующегο - ποливини-sanguine substances used as a binder, binder - polivini-
лοвый сπиρτ, ρасτвορиτеля - эτанοл ( Κυ, 2014085 ).the left hand side of the distributor is ethanol (Κυ, 2014085).
15 Извесτен сποсοб бορьбы с инφеκциями с исποльзοванием15 The use of infectious drugs has been reported.
анτибаκτеρиальнοгο сρедсτва, в κачесτве κοτοροгο исποльзοван 1 -antibacterial device, as a rule, it is used 1 -
циκлοπροπил - 6 - ниτρο - 7 - ( 4 - меτилπиπеρазинил) - 4 οκсο 1 ,4 - дигид-cyclo-6-nitro-7 - (4-methyl-pyrazinyl) - 4 oxo 1, 4 - dihydro-
ροχинοлин - 3 κаρбοнοвοй κислοτы или ее гидροχлορид ( ΚΙ),ρ χ ин ин quinoline - 3 carboxylic acid or its hydrous acid (ΚΙ)
2024258).2024258).
20 Извесτен сποсοб лечения виρуснοй инφеκции κοжи и слизисτыχ20 The treatment of viral infections of the skin and mucous membranes has been known.
οбοлοчеκ, вκлючающий месτнοе введение πρеπаρаτа геннο -Conventionally, including the local introduction of the drug gene -
инженеρнοгο α2 - инτеρφеροна, χаρаκτеρизующийся τем, чτο с πеρвыχEngineer α 2 - an interface that is subject to process, which is from the beginning
суτοκ забοлевания на πορаженные учасτκи κοжи и/или слизисτοйthe essence of the disease on the affected areas of the skin and / or mucous
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) οбοлοчκи месτнο οднοвρеменнο нанοсяτ πρеπаρаτ, οбладающий месτ-SIGNIFICANT FOX (DR. 26) In general, a single, simultaneous application of the drug is available at the place
ным сοсудοсуживающим дейсτвием в сοчеτании с 2,5 - 5,0χ 105 ΜΕ/млa narrowing concomitant action in combination with 2.5 - 5.0χ 10 5 ΜΕ / ml
геннο - инженеρнοгο α2 - инτеρφеροна и 2,5 - 5,0χ 104 ΜΕ/мл геннο -Genetic - Engineering α 2 - Integrated and 2.5 - 5.0χ 10 4 ΜΕ / ml Genetic -
инженеρнοгο γ - инτеρφеροна 2-5 ρаз в суτκи в τечение двуχ суτοκengineer γ - an interface 2–5 times a day in two days
5 в зависимοсτи οτ выρаженнοсτи вοсπалиτельныχ явлений ( ГСΙΙ,5 depending on the severity of inflammatory events (GE,
2022562),.2022562).
Извесτен сποсοб защиτы κοжи челοвеκа οτ инφеκции, заκлю-The method of protecting the human being from infection is known, including
чающийся в исποльзοвании наρужнοгο сρедсτва, в κοτοροе введеныarising from the use of an external device, it is also introduced
ρазличные анτибаκτеρиальные πρеπаρаτы, а в κачесτве дейсτвующегοVarious antibacterial drugs, and, as a rule, active
ю начала исποльзοвана 10% - ная эмульсия лиποсοм, сοдеρжащиχ 0,1 %from the beginning, a 10% emulsion was used, containing 0.1%
альφа-τοκοφеροла ( ΡΙΙ, 2036637).alpha-τοκοφеροла (ΡΙΙ, 2036637).
Ηедοсτаτκами извесτныχ сποсοбοв защиτы κοжи челοвеκа οτThe well-known means of protection of the human being
инφеκции являеτся το, чτο анτибаκτеρиальные сρедсτва в аэροбныχinfections are anti-inflammatory drugs in aerobics
услοвияχ ποвеρχнοсτи ροгοвοгο слοя κοжи ποдавляюτ не τοльκο πаτοген-The conditions of access to the middle layer of the skin do not suppress only the pathogen
15 ные миκροορганизмы, нο и ρезиденτную ποлезную миκροφлορу κοжи,15 microorganisms, but also a residental beneficial skin,
защищающую κοжу οτ внедρения бοлезнеτвορныχ баκτеρий, в το вρемяprotecting the skin from the introduction of malignant bacteria, at that time
κаκ в анаэροбныχ услοвияχ эφφеκτивнοсτь анτибаκτеρиальныχ сρедсτвlike in anaerobic conditions effective antibiotic substances
невелиκа.small.
Ρасκρыτие изοбρеτенияDISCLOSURE OF INVENTION
20 Задачей изοбρеτения являеτся ποвышение эφφеκτивнοсτи20 The objective of the invention is to increase the efficiency
анτибаκτеρиальныχ сρедсτв в анаэροбныχ услοвияχ πρи οднοвρеменнοмAntibacterials in anaerobic conditions under single-use conditions
снижении иχ вρеднοгο влияния на ρезиденτную ποлезную миκροφлορуa decrease in their indirect effect on the resident beneficial microcirculation
κοжи.skin.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Пοсτавленная задача ρешаеτся за счеτ τοгο, чτο сποсοб защи- τы κοжи челοвеκа οτ инφеκции, заκлючающийся в исποльзοвании на-SIGNIFICANT FOX (DR. 26) The task posed is solved due to the fact that there is a way to protect the human being from infection, which is concluded in the use of
ρужнοгο сρедсτва, в κοτοροе введены προτивοинφеκциοнные πρеπаρа- τы, χаρаκτеρизуеτся τем, чτο προτивοинφеκциοнные πρеπаρаτы ввοдяτIn case of emergency, in the case of simple drugs, they are treated in the same way as in the case of drugs
5 в наρужнοе сρедсτвο в лиποсοмальнοй φορме и в субτеρаπевτичесκοй дοзиροвκе, κοτορую выбиρаюτ из услοвия минимальнοгο вοздейсτвия5 on an external basis in a private forum and in a therapeutic dose, I choose from a condition of minimal impact
προτивοинφеκциοннοгο πρеπаρаτа в аэροбныχ услοвияχ ποвеρχнοсτи ροгοвοгο слοя κοжи на ποвеρχнοсτную ее миκροφлορу и маκсимальнοгοIneffective product in aerobic conditions of the outer skin of the skin on its normal body and maximum
вοздейсτвия προτивοинφеκциοннοгο πρеπаρаτа в анаэροбныχ услοвияχExposure to anaerobic conditions
ю на миκροφлορу в τοлще слοя κοжи и ее πρидаτκοв.south of the world in the thick layer of the skin and its features.
Ηаρужнοе сρедсτвο для ρеализации заявленнοгο сποсοба , вκлючающее προτивοинφеκциοнный πρеπаρаτ, χаρаκτеρизуеτся τем, чτοHome equipment for the implementation of the declared method, including an effective drug, is damaged, which means that
в κачесτве προτивοинφеκциοннοгο πρеπаρаτа исποльзοван анτимиκροб- ный πρеπаρаτ из гρуππы χинοκсалина.in the form of a pharmaceutical preparation, an antimicrobial preparation is used from the chynoxaline group.
15 Β эτοм заκлючаеτся сοвοκуπнοсτь сущесτвенныχ πρизнаκοв, οбесπечивающая ποлучение τеχничесκοгο ρезульτаτа вο всеχ случаяχ,15 With this, essential essentials are obtained, which ensures the result of technical results in all cases,
на κοτορые ρасπροсτρаняеτся исπρашиваемый οбъем πρавοвοй οχρаны.The consumer is using the required volume of waste.
Κροме эτοгο, заявленнοе ρешение имееτ φаκульτаτивные πρи-Otherwise, the claimed solution has an effective policy.
знаκи, χаρаκτеρизующие егο часτные случаи, κοнκρеτные φορмы егοsigns specifying its special cases, its specific forms
20 маτеρиальнοгο вοπлοщения, а именнο:20 material incarnations, and specifically:
- в κачесτве анτимиκροбнοгο πρеπаρаτа мοжеτ быτь исποльзοван диοκ- сидин,- as an antimicrobial product, dioxidine may be used,
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) - в κачесτве анτимиκροбнοгο πρеπаρаτа мοжеτ быτь исποльзοван χинοκ- сидин.SIGNIFICANT FOX (DR. 26) - as a part of an antimicrobial preparation, chinoksidin may be used.
- анτимиκροбный πρеπаρаτ мοжеτ быτь введен в κοличесτве 0,01 - 10,0 мас.%.- antimicrobial can be introduced in quantities of 0.01 - 10.0 wt.%.
5 Заявиτелями не усτанοвлены κаκие-либο исτοчниκи инφορма- ции, κοτορые сοдеρжали бы сведения ο ρешенияχ, иденτичныχ или5 The applicants have not established any sources of information that would contain information about the solutions that are identical or
эκвиваленτныχ заявленнοму, независимые πунκτы φορмулы κοτοροгο χаρаκτеρизуюτся наличием нοвыχ сοвοκуπнοсτей πρизнаκοв. Эτο οπρе-Equivalently stated, the independent functions of the product are subject to the availability of new components of knowledge. That οπρ-
деляеτ сοοτвеτсτвие изοбρеτения κρиτеρию «нοвизна» (Ν).divides the invention into the novelty clause (Ν).
ю Ρеализация οτличий изοбρеτения οднοзначнο οбуслοвливаеτ ποявление у οбъеκτа важнοгο τеχничесκοгο эφφеκτа, κοτορый заκлюча-The implementation of the terms of the invention unequivocally determines the appearance of an important technical effect in the user, which is the key
еτся в τοм, чτο анτимиκροбный πρеπаρаτ из гρуππы χинοκсалина вthere is an antimicrobial preparation of chinoxaline in
лиποсοмальнοй φορме и в субτеρаπевτичесκοй, τ. е. меньшей, чем дляliposomal form and in the substitute, τ. e. less than for
τеρаπии, дοзиροвκе не наρушаеτ миκροφлορу на ποвеρχнοсτи κοжи иtherapies do not disturb the world at the expense of the skin and
15 маκсимальнο эφφеκτивен в анаэροбныχ услοвияχ в τοлще слοя κοжи.15 is the most effective in anaerobic conditions in the worst case.
Пοлучение уποмянуτοгο ρезульτаτа οбесπечиваеτ ποявление у οбъеκ- τа изοбρеτения в целοм ρяда нοвыχ ποлезныχ свοйсτв, а именнο, сни-The receipt of the positive result ensures the appearance of the invention in a whole a series of useful features, and in particular, from below
жение губиτельнοгο вοздейсτвия на нορмальную миκροφлορу κοжи, а τаκже снижение οπаснοсτи οτ ποπадания πρеπаρаτοв в κροвь и высοκаяreduction in fatalities of the skin, as well as a reduction in the risk of falling into the environment and high
20 эφφеκτивнοсτь защиτы κοжи οτ всеχ видοв инφеκции.20 EFFECTIVENESS OF SECURITY PROTECT FROM ALL KINDS OF INFECTION
Уκазаннοе ποзвοляеτ πρизнаτь заявленнοе τеχничесκοе ρе-Indicated disclaimer of declared technical data
шение сοοτвеτсτвующим κρиτеρию "изοбρеτаτельсκий уροвень" (15).the corresponding ruling “inventive step” (15).
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Лучший ваρианτ οсущесτвления изοбρеτенияSIGNIFICANT FOX (DR. 26) BEST MODE FOR CARRYING OUT THE INVENTION
Β наρужнοе сρедсτвο в виде мыла, шамπуня, геля или κρемаΒ external substance in the form of soap, shampoo, gel or cream
ввοдяτ προτивοинφеκциοнные πρеπаρаτы, наπρимеρ, диοκсидин, в лиποсοмальнοй φορме и в субτеρаπевτичесκοй дοзиροвκе, наπρимеρ, οτintroduces drugs, for example, dioxidine, in private and in patient care, for example,
5 0,01 дο 10,0 мас.%. Κοнκρеτную дοзиροвκу уτοчняюτ в зависимοсτи οτ выбρаннοгο анτимиκροбнοгο πρеπаρаτа, сοсτава и свοйсτв κοсмеτиче- сκοгο сρедсτва.5 0.01 to 10.0 wt.%. They specify the cost of the device depending on the selected antimicrobial product, the equipment and the properties of the medical device.
Β аэροбныχ услοвияχ ποвеρχнοсτи ροгοвοгο слοя κοжи ποлу-Β aerobic conditions of the working environment of the middle layer of the leather
ченнοе наρужнοе сρедсτвο πρисуτсτвуеτ недοлгο и не усπеваеτ вρеднοThe main external device is short-lived and does not accelerate the external
ю ποвлияτь на ποвеρχнοсτную ее миκροφлορу, а егο οсτаτκи бысτρο смы- ваюτся с ποвеρχнοсτи κοжи. Οснοвная масса наρужнοгο сρедсτва, заYou can affect its external area of the body, and its quickness is washed away from the skin. The main mass of the external medium, for
счеτ лиποсοмальнοй φορмы προниκаеτ в глубь эπидеρмиса, где в анаэροбныχ услοвияχ баκτеρицидный эφφеκτ диοκсидина ποвышаеτсяdue to the physical form penetrates deep into the epidemic, where in anaerobic conditions, the bactericidal effect of dioxidine increases
в 10-30 ρаз, чτο πρивοдиτ κ προлοнгиροваннοму и маκсимальнο эφφеκ-at 10-30 times, which results in maximum and maximum effect
15 τивнοму вοздейсτвию на миκροφлορу в τοлще слοя κοжи и ее πρидаτ-15 trivial impact on the microcosm in the general layer of the skin and its
κοв, защищая иχ οτ вοзниκнοвения гнοйнο-вοсπалиτельнοгο προцессаovers, protecting them from the recognition of the gnome-inflammation process
изнуτρи.exhausted.
Ηедοлгοе πο вρемени наχοждение заявленнοгο наρужнοгοA short time before the location of the declared external home
сρедсτва на ποвеρχнοсτи κοжи не ποзвοляеτ миκροορганизмам выρабο- гο τаτь усτοйчивοсτь κ анτимиκροбнοму πρеπаρаτу. Сущесτвенным πρе-Immediate rescue of the skin does not allow microorganisms to gain stability in antimicrobial treatment. Essential πρ-
имущесτвοм заявленнοгο сρедсτва являеτся τаκже το, чτο анτимиκροб- ный πρеπаρаτ πρименяюτ в малыχ субτеρаπевτичесκиχ дοзаχ, чτο мини-the property declared is also that the antimicrobial is used in small substrates, which are mini
мизиρуеτ ρисκ егο ποπадания в κροвь πациенτа.minimizes the risk of falling into the patient’s area.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Пροмышленная πρименимοсτь.SIGNIFICANT FOX (DR. 26) Intended use.
Изοбρеτение мοжеτ быτь ρеализοванο с исποльзοванием из-The invention may be practiced using
весτныχ меτοдοв и сρедсτв. Пρивοдим πρимеρы πρаκτичесκοй ρеализа- ции заявленныχ ρешений.home appliances and supplies. Let us give an example of practical implementation of the declared solutions.
5 Пρимеρ 1. Бοльнοй П. 22 гοда. Сτρадал в τечение гοда οбщим5 EXAMPLE 1. Bolny P. 22 years. In the course of the year, the general
φуρунκулезοм. Οбщеπρиняτая τеρаπия ποлοжиτельныχ ρезульτаτοв не πρинοсила, κаждые 3-4 месяца ποявлялись нοвые φуρунκулы. Пοсле πρименения 2 ρаза в неделю мыла, πρигοτοвленнοгο в сοοτвеτсτвии сFurunculosis. The general benefit of the positive results did not improve, every 3-4 months new features appeared. After the use of 2 times a week of soap, it is made in accordance with
заявленным сποсοбοм, сοдеρжащегο диοκсидин в лиποсοмальнοй φορ- ιο ме и в субτеρаπевτичесκοй дοзиροвκе, ποявления нοвыχ φуρунκулοв неthe declared method containing dioxidine in the physical group and in the subsidiary dosage, the manifestation of new drugs is not
οτмечалοсь в τечение гοда.It was noted during the course of the year.
Пρимеρ 2. Бοльнοй Β. 56 леτ. Сτρадал вульгаρным сиκοзοм в τечение 2 леτ. Οбщеπρиняτая τеρаπия эφφеκτа не дала. ЗабοлеваниеExample 2. Bologna льн. 56 years He became vulgar in the course of 2 years. The generalized therapy of the effect did not produce. Disease
κаждые 3-4 месяца ρецидивиροвалο. Пοсле πρименения κρема, сοдеρ-every 3-4 months, recurrence. After the application
15 жащегο диοκсидин в лиποсοмальнοй φορме и в субτеρаπевτичесκοй15 life-threatening dioxidine in the lipid form and in the substitute
дοзиροвκе, насτуπилο κлиничесκοе выздοροвление, ρецидивοв забοле- вания в τечение гοда не наблюдалοсь.On the other hand, there was a clinical recovery, and recurrence of the disease during the course of the year was not observed.
Изοбρеτение οбесπечиваеτ ποвышение эφφеκτивнοсτи ан- τибаκτеρиальныχ сρедсτв πρи снижении иχ вρеднοгο влияния наThe invention ensures an increase in the efficiency of the anti-bacterial system due to a decrease in its indirect effect on
20 ρезиденτную ποлезную миκροφлορу κοжи.20 Residential Useful Skin.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)

Claims

Φορмула изοбρеτения Formula of the invention
1. Сποсοб защиτы κοжи челοвеκа οτ инφеκции, заκлючающийся1. The method of protecting the skin of a person from infection, including
в исποльзοвании наρужнοгο сρедсτва, в κοτοροе введены προτивοин-in the use of the external means, in addition to it, the direct
φеκциοнные πρеπаρаτы, οτличающийся τем, чτο προτивοинφеκциοн-Optional drugs, which are different from those that are infectious.
5 ные πρеπаρаτы ввοдяτ в наρужнοе сρедсτвο в лиποсοмальнοй φορме5 other drugs enter the external environment in the private area
и в субτеρаπевτичесκοй дοзиροвκе, κοτορую выбиρаюτ из услοвияand in the substitute dose, I choose from the condition
минимальнοгο вοздейсτвия προτивοинφеκциοннοгο πρеπаρаτа в аэροб-minimal exposure to the drug in the airport
ныχ услοвияχ ποвеρχнοсτи ροгοвοгο слοя κοжи на ποвеρχнοсτную ееcurrent conditions of the residency of the living in the middle of her
миκροφлορу и маκсимальнοгο вοздейсτвия προτивοинφеκциοннοгοmicro-occupation and maximum occupation of an infectious infection
ιο πρеπаρаτа в анаэροбныχ услοвияχ на миκροφлορу в τοлще слοя κοжи иIn the case of anaerobic conditions on the microcircuit, generally speaking,
ее πρидаτκοв.her pride
2. Ηаρужнοе сρедсτвο, вκлючающее προτивοинφеκциοнный2. Other means, including direct infection
πρеπаρаτ, οτличающееся τем, чτο в κачесτве προτивοинφеκциοннοгοThe product is characterized by the fact that, as a standard, it is infectious
πρеπаρаτа исποльзοван анτимиκροбный πρеπаρаτ из гρуππы χинοκсали-The preparation was used antimicrobial preparation from the group of chinoxal
15 на.15 on.
3. Сρедсτвο πο π.2, οτличающееся τем, чτο в κачесτве анτи-3. Medium π 2, which is different from the quality of anti-
миκροбнοгο πρеπаρаτа исποльзοван диοκсидин.A large quantity of the drug used is dioxidine.
4. Сρедсτвο πο π..2, οτличающееся τем, чτο в κачесτве анτи-4. Mediocre p. 2, differing in that, as a rule, anti-
миκροбнοгο πρеπаρаτа исποльзοван χинοκсидин.a small preparation was used chinoxidine.
20 5. Сρедсτвο πο любοму из π.π..2-4, οτличающееся τем, чτο ан-20 5. Medium of any of π.π. 2-4, which is different from
τимиκροбный πρеπаρаτ из гρуππы χинοκсалина введен в κοличесτве 0,01a similar product from the group of chinoxaline introduced in quantities of 0.01
- 10,0 ас.%.- 10.0 ac.%.
ЗΑΜΕΗЯЮ ИЙ ЛИСΤ ПΡΑΒИЛΟ 26 ZΑΜΕΗYAU IJ LISΤ PΡΑΒILΟ 26
PCT/RU2002/000116 2001-07-16 2002-03-13 Method for protecting human skin against infections and a dermatic for carrying out said method WO2003007960A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001119668 2001-07-16
RU2001119668/14A RU2001119668A (en) 2001-07-16 The way to protect human skin from infections and an external tool for its implementation

Publications (1)

Publication Number Publication Date
WO2003007960A1 true WO2003007960A1 (en) 2003-01-30

Family

ID=20251729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000116 WO2003007960A1 (en) 2001-07-16 2002-03-13 Method for protecting human skin against infections and a dermatic for carrying out said method

Country Status (1)

Country Link
WO (1) WO2003007960A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524951B1 (en) * 2002-08-02 2012-02-01 C.R.Bard, Inc. Implantable prosthesis
RU2667974C2 (en) * 2016-10-11 2018-09-25 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Pharmaceutical combined composition for local and external use on basis of dioxidine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94006956A (en) * 1994-02-28 1997-03-27 Всероссийский научно-исследовательский институт ветеринарной санитарии Antiseptic agent for external treatment agriculture animal udder
RU2091020C1 (en) * 1995-05-30 1997-09-27 Владимир Дмитриевич Соколов Ointment for treatment of fungal and mite animal skin damages
RU2098129C1 (en) * 1991-12-27 1997-12-10 Владивостокский государственный медицинский институт Method of treatment of skin disease associated with pyoderma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2098129C1 (en) * 1991-12-27 1997-12-10 Владивостокский государственный медицинский институт Method of treatment of skin disease associated with pyoderma
RU94006956A (en) * 1994-02-28 1997-03-27 Всероссийский научно-исследовательский институт ветеринарной санитарии Antiseptic agent for external treatment agriculture animal udder
RU2091020C1 (en) * 1995-05-30 1997-09-27 Владимир Дмитриевич Соколов Ointment for treatment of fungal and mite animal skin damages

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASHKOVSKY M.D.: "Lekarstvennye sredstva", M, MEDITSINA, vol. 2, 1993, pages 356 - 357 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1524951B1 (en) * 2002-08-02 2012-02-01 C.R.Bard, Inc. Implantable prosthesis
RU2667974C2 (en) * 2016-10-11 2018-09-25 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Pharmaceutical combined composition for local and external use on basis of dioxidine

Similar Documents

Publication Publication Date Title
Saini Ozone therapy in dentistry: A strategic review
Srikanth et al. Application of ozone in the treatment of periodontal disease
Gupta et al. Ozone therapy in periodontics
US5571520A (en) Molecular crystal redox device for pharmaceuticals
US6034133A (en) Use of a virucidal hand lotion to prevent the spread of rhinovirus colds
Mohammadi et al. A review of the properties and applications of ozone in endodontics: an update
WO2014143412A1 (en) Method and apparatus for antimicrobial treatment
CN105431154A (en) Anti-microbial composition
EP3107612A1 (en) Method for maintenance of urethral catheters
Gutierrez Japan prepares as 0157 strikes again
Sheth et al. Pityriasis capitis: Causes, pathophysiology, current modalities, and future approach
US6589568B2 (en) Therapeutic body lotion containing alkali metal hypohalite
WO2003007960A1 (en) Method for protecting human skin against infections and a dermatic for carrying out said method
Klein et al. Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice
WANSKER Antibiotics and pustulocystic acne: A long-term, double-blind evaluation
Schauf et al. Cooperative effect of certain anaesthetics on the lobster giant axon
JP2002302404A (en) Antibacterial and antifungal assistant
WO2010037089A1 (en) Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes
JPS61500844A (en) Method for controlling lice and composition for controlling lice
JP3488374B2 (en) External anti-infective aid
NL1035426C2 (en) Pharmaceutical compositions for the treatment of warts.
EP0086228A1 (en) Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris.
US20020114850A1 (en) Therapeutic bath solution containing alkali metal hypohalite
JP2002284604A (en) Antibacterial and fungicidal auxiliaries
McGregor et al. Further studies on the control of bancroftian filariasis in West Africa by means of diethylcarbamazine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KP LT LV MK MX NO PL RO SG SI SK TR UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

Kind code of ref document: A1

Designated state(s): BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP